Business
Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk
First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremitiesProtocol involves one or two PDT treatments using 1-3 tubes of Ameluz® or vehicle gel over a surface area of up to 240 cm2Treatment phase expected to be complete by Q3 2025 WOBURN, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today a
About this update from Biofrontera Inc.
[{"type":"image","alt":"Biofrontera Inc.","displaySize":"","headline":null,"caption":"Biofrontera Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/f8bea715aa1dcdf4aff565eecd02fa4b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bVH36b1WxYUx1e199mXo7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f8bea715aa1dcdf4aff565eecd02fa4b","width":300,"height":150}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremities","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"Protocol involves one or two PDT treatments using 1-3 tubes of Ameluz® or vehicle gel over a surface area of up to 240 cm2","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"Treatment phase expected to be complete by Q3 2025","length":50,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":263,"olType":false},{"type":"text","content":"WOBURN, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the enrollment of the final patient in its Phase 3 clinical trial evaluating Ameluz® (aminolevulinic acid hydrochloride) for the treatment of mild to moderate actinic keratoses (AKs) on the extremities, neck and trunk. Actinic keratosis is a common skin condition found on sun-exposed areas of the body, and if left untreated, may progress to squamous cell carcinoma. Expanding field treatment options for AKs beyond the face and scalp would address a critical unmet need in dermatology.","length":732,"tagName":"p"},{"type":"text","content":"This trial is a multicenter, randomized, double-blind study comparing Ameluz® with vehicle in the field-directed treatment of actinic keratoses (AK) located on the extremities, neck and trunk with PDT using a RhodoLED lamp (BF-RhodoLED® XL or BF-RhodoLED®). It is designed to assess the safety and efficacy of Ameluz® PDT following the application of 1-3 tubes of product over a surface area (continuous or in patches) of approximately 80, 160 or 240cm2. Patients receive one PDT treatment with either Ameluz® ...